DENTSPLY SIRONA (XRAY) Projected to Post Earnings on Thursday

DENTSPLY SIRONA (NASDAQ:XRAY) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $0.3117 per share and revenue of $861.65 million for the quarter. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The business had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. During the same quarter in the previous year, the firm earned $0.52 earnings per share. The company’s revenue for the quarter was down 4.1% on a year-over-year basis. On average, analysts expect DENTSPLY SIRONA to post $1.39 EPS for the current fiscal year and $1.49 EPS for the next fiscal year.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $9.44 on Thursday. The company has a market capitalization of $1.88 billion, a P/E ratio of -3.43, a P/E/G ratio of 1.20 and a beta of 0.87. DENTSPLY SIRONA has a 1-year low of $8.32 and a 1-year high of $14.76. The firm’s 50 day simple moving average is $9.75 and its two-hundred day simple moving average is $11.37. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on XRAY shares. Weiss Ratings restated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. Barrington Research dropped their target price on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating for the company in a report on Monday. Barclays increased their price target on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research note on Monday, August 24th. Mizuho decreased their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, October 22nd. Finally, Leerink Partners decreased their target price on DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 14th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, DENTSPLY SIRONA currently has a consensus rating of “Hold” and an average target price of $12.62.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.